Community-acquired pneumonia: Influence of the duration of intravenous antibiotic therapy on hospital stay and the cost-benefit ratio;Neumonía adquirida en la comunidad: Influencia de la duración de la antibioterapia intravenosa en la estancia hospitalaria y relación coste/efectividad

Archivos de Bronconeumologia

Volumn 37, Issue 9, 2001, Pages 366-370

  Fernandez Alvarez R ^a,b   Gullon Blanco J A ^a   Rubinos Cuadrado, G ^a   Jimenez Sosa A ^a   Hernandez Garcia C ^a   Medina Gonzalvez A ^a   Gonzalez Martin I ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b NONE   (Spain)

Author keywords

Community acquired pneumonia; Cost benefit; Intravenous antibiotic therapy

Indexed keywords

ANTIINFECTIVE AGENT;

AGED; ARTICLE; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; TIME;

AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA; TIME FACTORS;

EID: 0346347527     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-2896(01)78816-3     Document Type: Article

References (15)

1. Siegel R, Halpern N, Almenoff P, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv antibiotics for community-acquired pneumonia. Chest 1996; 110: 965-971.
2. Vogel F. Sequential therapy in the hospital management of lower respiratory infections. Am J Med 1995; 99: B6-S14.
3. Nathwani D. Sequentional switch therapy for lower respiratory tract infections. A European perspective. Chest 1998; 113: S211-S218.
4. Ramírez J, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-1276.
5. McCormick D, Fine MJ, Coley CM et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am J Med 1999; 107: 5-12.
6. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
7. Omidvari K, De Boisblanc B, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998; 92: 1032-1039.
8. Rhew D, Riedinger M, Sandhu M, Bowers C, Greengold N, Weingarten SR. A prospective, multicenter study of a pneumonia practice guideline. Chest 1998; 114: 115-119.
9. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997; 10: 1530-1534.
10. Rhew D, Hackner D, Henderson L, Ellrod AG, Weingarten SC. The clinical benefit of in-hospital observation in "low-risk" pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest 1998; 113: 142-146.
11. Dunn A, Peterson K, Schechter C, Rabito P, Gotlin AD, Smith LG. The utility on an in-hospital observation period after discontinuing intravenous antibiotics. Am J Med 1999; 106: 6-10.
12. Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. Br Med J 1995; 310: 1360-1362.
13. Daifuku R, Movahhed H, Fotherighan N, Bear MB, Nelson S. Time to resolution of morbidity: an endpoint for assessing the clinical cure of community-acquired pneumonia. Respir Med 1999; 90: 587-592.
14. Ferrando D, Menéndez R, Cordero P, Vallés JM, Martínez E, Perpiñá M. Neumonía adquirida en la comunidad. Análisis de la duración de las estancias hospitalarias según el grado de riesgo. Aplicación de la escala de Fine. Arch Bronconeumol 1999; 35 (Supl 2): 72.
15. Dorca J, Bello S, Blanquer J, De Celis R et al. Diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Arch Bronconeumol 1997; 33: 240-246.